Background

Either deletion or co-deletion of chromosomal arms 1p or 19q is a characteristic and early genetic event in oligodendroglial tumors that is associated with a better prognosis and enhanced response to therapy. Information of 1p/19q status is now regarded as the standard of care when managing oligodendroglial tumors for therapeutic options in anticipation of the increased survival and progression-free survival times associated with it. Keeping this in view, we first time attempted to establish the FISH based detection of 1p/19q deletion in glioma tissue samples to evaluate its role and involvement in the disease.

Method

Overall 39 glioma cases of different histologies were evaluated by fluorescence in situ hybridization (FISH) technique using specific FISH probes with Olympus BX43 fluorescent microscope to detect chromosomes 1p and 19q or co-deletions therein.

Results

Of the 39 glioma samples, overall 27 (69.2%) were found to have deletion either in 1p, 19q or both. Deletions were observed in 23.0%, 7.6% and 38.4% in 1p, 19q and 1p/19q co-deletions respectively. Overall oligidendrioglioma presented with 53.8% (21 of 39) deletions, astrocytoma group showed 12.8% and GBM accounted for 2.5% deletions. Overall survival and disease free survival was seen significantly better in oligidendrioglioma and astrocytoma with deleted tumors as compared to non-deleted ones (p<0.05).

Conclusion

Allelic losses on 1p and 19q, either discretely or shared, were more frequent in classic oligodendrogliomas than in either astrocytoma or Glioblastoma with better survival and response to therapy.

中文翻译：

---

荧光原位杂交（FISH）评估染色体 1p/19q 缺失作为烷化化疗恶性胶质瘤患者的预后因素

背景

染色体臂 1p 或 19q 的缺失或共同缺失是少突胶质细胞肿瘤的特征性早期遗传事件，与更好的预后和增强的治疗反应相关。1p/19q 状态的信息现在被视为管理少突胶质细胞肿瘤的治疗选择时的护理标准，以预期与之相关的生存期和无进展生存时间的增加。鉴于此，我们首次尝试建立基于 FISH 的神经胶质瘤组织样本中 1p/19q 缺失检测，以评估其在疾病中的作用和参与。

方法

通过荧光原位杂交（FISH）技术，使用特定的 FISH 探针和奥林巴斯 BX43 荧光显微镜检测总共 39 例不同组织学的胶质瘤病例，检测染色体 1p 和 19q 或其中的共缺失。

结果

在 39 个神经胶质瘤样本中，总共有 27 个（69.2%）被发现在 1p、19q 或两者都有缺失。1p、19q 和 1p/19q 共缺失中观察到的缺失率分别为 23.0%、7.6% 和 38.4%。总体而言，少突神经胶质瘤有 53.8%（39 个中的 21 个）缺失，星形细胞瘤组有 12.8%，GBM 组有 2.5% 缺失。与未删除的肿瘤相比，删除肿瘤的少突神经胶质瘤和星形细胞瘤的总生存率和无病生存率明显更高（p <0.05）。

结论

1p 和 19q 等位基因丢失（无论是离散的还是共有的）在经典少突胶质细胞瘤中比在星形细胞瘤或胶质母细胞瘤中更常见，并且具有更好的生存率和对治疗的反应。